Please select the option that best describes you:
When do you evaluate patients with Parkinson's disease and cognitive decline for concurrent Alzheimer's disease?
Are such patients candidates for anti-amyloid therapy?
Answer from: at Academic Institution
Parkinson’s disease (PD) often includes Alzheimer’s disease (AD) “co-pathology” in up to 80% of cases. This challenges the notion that PD is a synucleinopathy; it affects many proteins beyond α-synuclein. Thus, cognitive decline in PD may be associated with AD pathology...
Sign in or Register to read more
Answer from: at Academic Institution
In general, I always ask myself and the patient, "What will we do with the results of a test?" Cognitive decline is part of Parkinson's disease (PD). Symptomatic treatment with rivastigmine (or other acetylcholinesterase inhibitors) and memantine can be helpful without the need for further testing f...